News | January 01, 2025
Sanofi acquires rights to develop and commercialize Aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Merck has also decided to end the favezelimab clinical development program
The trademark rights for these brands will be transferred to Lupin by March next year.
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
First and only PARP inhibitor to improve overall survival in early breast cancer
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Subscribe To Our Newsletter & Stay Updated
